将饮食模式与阿尔茨海默病生物标志物与网络数学建模联系起来,可以使预防性阿尔茨海默病研究中的新方法方法成为可能:一个叙事性的跨学科审查
Travis B Thompson1,2,3,4,5, Andrew C Shin1,3,4,5,6, Boris Decourt1,3,7
1Institute for One Health Innovation, Texas Tech University System, Lubbock, TX, United States.
Frontiers in nutrition
|January 28, 2026
概括
预防性饮食策略可能有助于抑制阿尔茨海默病 (AD) 的流行. 本综述探讨了使用数学和计算模型 (新方法方法或NAM) 来将饮食与AD病理联系起来,帮助预防性研究.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默氏病 (AD) 是一个重大的全球健康挑战,目前没有药物治疗方法.
- 饮食模式与三分之一的AD风险因素有关,并可能影响疾病的发病和进展.
- 现有的关于饮食在阿尔茨海默病中的预防作用的人类和动物研究面临着成本和道德等挑战.
研究的目的:
- 引入跨学科团队开发基于数学或模拟的新方法方法 (AD-NAM).
- 探索饮食模式在抑制AD患病率方面的潜力,直到有效的药物治疗方法可用为止.
- 弥合当前研究和计算方法之间的差距,以调查饮食与AD的联系.
主要方法:
- 这篇叙述性综述介绍了开发基于模拟的AD-NAM的三个关键领域.
- 它涵盖了AD蛋白生物标记病理,饮食对这种病理的影响,以及网络数学模型.
- 该评论讨论了用于分析AD病理和模拟饮食影响的计算和数学建模.
主要成果:
- 饮食模式是阿尔茨海默病的重要可修改的风险因素.
- 数学和计算模型 (AD-NAM) 为研究饮食和AD关系提供了一个有希望的途径.
- 网络数学模型可以模拟由饮食因素影响的AD病理的进展.
结论:
- 开发基于模拟的AD-NAM对于理解饮食和AD病理之间的机制联系至关重要.
- 饮食干预有潜力抑制AD的患病率.
- 跨学科的合作对于推进AD研究中的计算方法至关重要.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
09:47DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...